GVR Report cover Infertility Treatment Drugs Market Size, Share & Trends Report

Infertility Treatment Drugs Market Size, Share & Trends Analysis Report By Drug Class (Gonadotropins, Aromatase Inhibitors), By Demographic, By Distribution Channel, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453620
  • Number of Pages: 0
  • Format: Electronic (PDF)

Globally, infertility affects millions of people of reproductive age, thereby directly impacting their families and community. Male infertility is majorly due to factors such as premature ejaculation, low sperm count, and other ejection-associated implications, whereas female incapability is due to several abnormalities in the uterus, ovaries, fallopian tubes, and the endocrine system, among others. The rising burden of such conditions offers a lucrative opportunity for the market. According to WHO, in 2020, around 48 million couples and 186 million individuals are experiencing infertility worldwide.

Medical conditions such as hyperprolactinemia, thyroid problems, and polycystic ovary syndrome (PCOS) are the major factors interfering with ovulation in females and it is reported that 25% of female cases are due to ovulation disorder. Furthermore, the rise in the incidence is also recorded due to increasing sedentary lifestyle, excessive alcohol consumption, smoking, obesity, stress, and many more leading to growing demand in the infertility treatment drugs market.

Infertility treatment drugs market has been segmented by drug class as:

  • Gonadotropins

  • Aromatase Inhibitors

  • Selective Estrogen Receptor Modulators (SERMs)

  • Biguanides

  • Others

The space has a substantial presence of Gonadotropins, Selective Estrogen Receptor Modulators (SERMs), follicle-stimulating hormone (FSH), biguanides, and aromatase Inhibitors. Common female treatment drugs include gonadotropins, Clomiphene citrate, Metformin, Letrozole, and Bromocriptine. Male drug treatment contains medications such as vardenafil (Levitra), tadalafil, and avanafil (Stendra) to manage the condition.

Growing innovation and R&D of novel therapeutics are anticipated to offer a lucrative opportunity for infertility treatment drugs market growth over the coming years. This includes pipeline candidates such as Oxolife (OXO-001) and nolasiban, which are indicated to control fertility complications and are expected to be breakthrough innovations in reproductive treatment.

Furthermore, insurance companies have shown interest in covering infertility therapeutics; such factors further support space growth. For instance, in 2022, InsurMedix introduced the AI-based platform with USD 75 million in funding, which cover fertility improvement treatment drugs in the U.S. Such initiatives have new standards of medical care for individual and families by covering infertility treatment drugs.

Key market players are undertaking initiatives for new approval and launches, mergers, and regional expansions to maintain a healthy position in the space. For instance, in August 2021. Merck KGaA announced the launch of ready to use Pergoveris Pen, a combination of recombinant LH and FSH in the Indian market.

Infertility Treatment Drugs Market Segmentation

Segments

Details

Drug Class

Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Biguanides, Others

Demographic

Male and Female

Distribution Channel

Hospital pharmacies, Retail pharmacies, Online pharmacies

Region

North America; Europe; Asia Pacific; Latin America; Middle East and Africa (MEA)

 

Major companies operating in the market include Bayer AG, Novartis AG, Merck KGaA, Pfizer Inc., Ferring Pharmaceuticals Inc., Mankind Pharma, Teva Pharmaceutical Industries Ltd., and Sanofi S.A., amongst others.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon